[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model].
Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies. However, the mechanisms of the development of cancer cachexia remain to be elucidated. Interleukin (IL)-6 is known to be involved in the development of cancer cachexia. The KPL-4 human breast cancer cell line, which was recently established in our laboratory, secretes IL-6 into the culture medium. Oral administration of doxifluridine (5'-DFUR, 60 mg/kg or 120 mg/kg) significantly inhibited the growth of KPL-4 tumors, reduced the tissue levels of IL-6, and alleviated body weight loss. Serum IL-6 levels were also lowered by 5'-DFUR in nude mice bearing KPL-4 tumors. Additionally, it is suggested that tumor necrosis factor (TNF)-alpha is involved in the cachexia induced by KPL-4 tumors. We suggest that 5'-DFUR suppresses cancer cachexia by lowering IL-6 levels in the tumor tissues and serum.
Yamamoto
S
S
Dept. of Breast and Thyroid Surgery, Kawasaki Medical School.
Kurebayashi
J
J
Kunisue
H
H
Udagawa
K
K
Yamamoto
Y
Y
Arime
I
I
Tanaka
K
K
Shimozuma
K
K
Sonoo
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology; D002100:Cachexia / Q000276:immunology / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D005260:Female; D005467:Floxuridine / Q000494:pharmacology*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010430:Pentosyltransferases / Q000378:metabolism; D057845:Pyrimidine Phosphorylases; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D015850:Interleukin-6; D005467:Floxuridine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; C025034:doxifluridine